Summary A simple colorimetric test, the MTT assay, has been adapted for chemosensitivity testing of human small cell lung cancer cell lines, and fresh tumour samples. Optimal conditions for clinical chemosensitivity testing were determined using established SCLC lines. Nineteen different chemotherapeutic agents were tested, and sixteen of them were found to be cytotoxic in this assay system. The drug sensitivity of a panel of 16 SCLC cell lines was measured and compared. There was very little intraexperiment variation, but the interexperiment variation was significant. Cell lines which were derived from patients who had not received chemotherapy at the time the cell line was established were more sensitive (to all but one of the drugs) than lines derived from treated patients, and the differences were statistically significant for two of the drugs. One cell line, NCI-H209, which was derived from an untreated patient, stood out as being the most sensitive or among the most sensitive to all of the drugs tested. Another cell line, H69AR, which is a multidrug resistant subline of the cell line NCI-H69, was the most resistant to many of the natural product drugs tested. Multiple drug chemosensitivity testing was performed on eight fresh tumour samples from SCLC patients (five pleural effusions, one lymph node, and two primary tumours). It was possible to perform chemosensitivity testing on all of the clinical samples in which sufficient tumour cells were available. The drug sensitivity of the clinical samples was, in most cases, within the same range as for the cell lines. Since this assay is very rapid and simple to perform, it may have practical applications in clinical drug sensitivity testing of human tumours.
Lung cancer has become an epidemic in North America, accounting for over 100,000 deaths annually. Small cell lung cancer comprises 20 to 25% of these cases. Although the prognosis in SCLC has improved considerably with the use of chemotherapy, and response rates are high, only a minority of patients are cured of the disease. A therapeutic plateau has now been reached, and new approaches are required to improve the results of treatment with currently available chemotherapeutic agents.
The results of empiric selection of chemotherapeutic drugs for treatment of individual patients with lung cancer could be improved by the use of a practical predictive assay of drug sensitivity. To aid in making therapeutic decisions, such an assay should be simple, rapid, inexpensive, and available to most patients. The clonogenic assay of Hamburger and Salmon (1977) has been used for predictive chemosensitivity testing, and positive clinical correlations have been found in a variety of tumour types (Browman et al., 1983; Park et al., 1980; Von Hoff et al., 1981) , including lung cancer (Shimizu et al., 1981) . However, the assay is highly labour-intensive, results are not available for 2-3 weeks, and numerous technical and theoretical problems remain Selby et al., 1983; Twentyman, 1985) .
As a result, there has been renewed interest in short term assays of drug sensitivity (Weisenthal & Lippman, 1985) . The MTT assay is a simple colorimetric test of cell proliferation and survival which was developed by Mosmann (1983) and adapted by Cole (1986) and others for measuring chemosensitivity of human lung cancer cell lines. A number of groups have used this assay for drug sensitivity testing of human cell lines (Carmichael et al., 1987 (Carmichael et al., , 1988 Finlay et al., 1986; Park et al., 1987; Twentyman & Luscombe, 1987) , and it is now being used for screening new anticancer agents (Alley et al., 1988 , Ruben & Neubauer, 1987 . It has also been used for chemosensitivity testing of fresh human leukaemia samples (Campling et al., 1988; Pieters et al., 1989; Twentyman et al., 1989) . In most instances, there is a close correlation between results of drug sensitivity testing using this assay and the clonogenic assay (Carmichael et al., 1987; Wasserman & Twentyman, 1988) . Because of its simplicity, the MTT assay has the potential to overcome a number of the problems encountered with other chemosensitivity assays which have prevented their routine use in clinical practice.
The purpose of the present investigation was to adapt the MTT assay for chemosensitivity testing of fresh human SCLC tumour samples. Initial experiments were performed using human SCLC cell lines in order to determine appropriate seeding cell densities, drug concentrations and drug incubation times. Once optimal conditions were determined, the chemosensitivity of a panel of SCLC cell lines was measured and compared. In addition, eight fresh tumour samples from SCLC patients were tested for their sensitivity to a broad range of chemotherapeutic agents. Although the MTT assay has been used extensively for chemosensitivity testing of human tumour cell lines, to the best of our knowledge, there have been no previous published reports of its use for chemosensitivity testing of human solid tumours.
Materials and methods

Cell lines
The cell lines used for this study are described in Table I . The source of the lines, and the treatment and response histories of the patients from whom the lines were derived are indicated in this table. Many of the lines were established in this laboratory and will be described in detail in a future publication. The cell lines NCI-H69, NCI-H128, and NCI-H209 were provided by Dr J. Minna, NCI-Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland (Carney et al., 1985) . H69AR is a multidrug resistant variant of NCI-H69, which was selected in Adriamycin (Mirski et al., 1987) . Cell line Mar was a gift from Prof. A. Neville, Ludwig Institute for Cancer Research, London, UK (Ibson et al., 1987 (Carney et al., 1985) H69AR Multidrug-resistant variant of NCI-H69 selected in S.P.C. Cole (Mirski, Gerlach & adriamycin.
Cole, 1987) NCI-H 128 Pleural effusion from a patient who had received chemotherapy.
J.D. Minna (Carney et al., 1985) NCI-H209 Bone marrow from an untreated patient.
J.D. Minna (Carney et al., 1985) Mar Derived from an untreated patient. A. Neville (Ibson et al., 1987) SHP-77
Primary tumour from a patient who had not received chemotherapy. Drug sensitivity studies were performed on eight of these samples (numbers 1, 3, 7, 8, 13, 14, 16 and 17 Effect of cell density on cytotoxicity It is difficult to obtain highly accurate cell counts using SCLC cell lines because the cells often form tight aggregates. Because of concerns that drug induced cytotoxicity might be affected by the seeding cell density (Chambers et al., 1984; Ohnuma et al., 1986) The dose response curves were normalised so that the baseline absorbance with no added drug was given a value of one. Two summary statistics were used for describing and comparing the dose response curves, namely the IC50 (the concentration of drug which caused 50% reduction in absorbance compared to baseline values), and the area under the dose response curve (AUC). The IC-% was derived by fitting a fourth degree polynomial regression to the data, and the AUC was calculated between drug concentrations of 0 and 100 jig ml-' by the trapezoidal method (Moon 1980) . The same concentration range was used for all of the drugs.
The intraexperiment variation (or repeatability) of the assay was assessed by determining the standard deviation of the AUC. This was done by generating a family of dose response curves by connecting the four data points at each drug concentration to each of the four data points at all of the other drug concentrations. The AUC for each of these curves was determined, and the mean AUC and standard deviation calculated. The interexperiment variation (or reproducibility) of the assay was determined by calculating the mean and standard deviation for the AUC of repeated tests with the same drug and cell line. All statistical analyses were performed using the SAS statistical package (SAS Institute Inc., 1985) .
Clinical correlation
The cell lines were classified according to the treatment status of the patients from whom the lines were established. This information is provided in Table I . It can be seen that cell lines BK-T, LG-T, HG-E, NCI-H209, Mar, and were derived from untreated patients, and cell lines AD-A, JO-E, WL-E, JN-M, SH-A, RG-1, MM-1, NCI-H69, and NCI-H128 were derived from treated patients. The cell line H69AR was excluded from this analysis, since it had undergone in vitro selection for drug resistance. The mean AUC for all of the cell lines from untreated patients was determined for each of the drugs and compared to the mean AUC for the cell lines from treated patients. Analysis of variance was applied to determine the statistical significance of the differences between cell lines from untreated patients and from treated patients for each of the drugs. A similar comparison was made for the clinical samples.
Results
Sixteen of the 19 drugs tested were cytotoxic in this assay. Procarbazine, methotrexate, and CCNU did not cause cytotoxicity and the reasons for this are unclear at the present time. It was possible to perform chemosensitivity testing with multiple drugs on all of the cell lines and on eight of the clinical samples (all of the samples in which sufficient tumour cells were obtained).
Cell density
The relationship of cell density to absorbance is shown in Figure 1 (Vichi & Tritton, 1989) . For these reasons, the AUC has been used to express the cytotoxicity data. The details of the statistical analysis are presented elsewhere (Lam et al., 1989) Another cell line, H69AR, which was selected for resistance to adriamycin and is known to be multidrug resistant (Mirski et al., 1987) (2) AD-128 (2) MAR (2) JN (2) HO9 (4) LG ( AD (2) H69 (5t BK (3) WL (2) 128 (3) RG-
LG ( LG (3) JO. 13.8 ± 0.3 28.3 +1.0 18.7 +1.5 15.6 ± 0.4 Vincristine 30.7-84.1 54.1 ± 3.4 68.3 ± 9.2 60.0 ± 2.0 84.9 ± 2.2 55.4 ± 1.0 72.0 ± 1.6 59.7 ± 2.8 68.5 ± 2.0 VM26 5.0-32.9 N.T. 17.5 ± 2.0 N.T.
28.0 ± 1.6 9.4 ± 0.4 27.0 ±+0.9 34.0 ± 1.6 45.8 ± 1.9 VP16 33.0-86.6 53.9 ± 1.6 54.3 4.0 81.7 2.6 120.6 4.7 57.9 1.0 95.6 ± 2.8 59.4 2.2 67.3 2.5 4H-Cyclophosphamide 11.1-55.2 N.T. 25.0 3.1 50.9 0.7 90.9 1.5 74.9 2.2 92.2 ± 3.0 30.1 ± 1.0 88.1 2.4
The clinical history of the patients in whom drug sensitivity testing was performed is indicated in the Materials and methods section. were only four patients in each group, and it was not possible to make any comment about the response status of the untreated patients, since one of them died before treatment could be given, two of them had their tumours resected, and were thus not assessable for response to chemotherapy, and one had a very minimal response to subsequent treatment.
Discussion
The use of a predictive assay of drug sensitivity could have an impact on the management of patients with lung cancer. In fact, a recently reported clinical trial in extensive SCLC comparing empiric selection of chemotherapy to selection based on the results of chemosensitivity testing suggests that response rates may be improved by this approach (Gazdar et al., 1990) . The clonogenic assay has proven to be of limited practical use since drug sensitivity testing can be performed in only a minority of lung cancer cases (De Vries et al., 1987; Kitten et al., 1982) , although improved culture techniques have resulted in higher success rates (Kanzawa et al., 1987) .
The major advantages of the MTT assay are its speed and simplicity. Because most steps are automated, it is possible to test multiple drugs, each at several concentrations. The automated data analysis is essential in view of the large amounts of data that can be generated. Since results are available within 3 days, such information may be of value in clinical therapy. Furthermore, a short assay duration will minimise the variable effects of cell proliferation and cell death over the assay period.
In order to perform testing of multiple drugs, relatively large numbers of cells are required. However, the test as we describe it requires no more cells than the clonogenic assay, or the DiSC assay of Weisenthal (Weisenthal et al., 1983) , which, when applied to lung cancer, requires 2 x 105 cells per data point (De Vries et al., 1987) .
It has been argued that the potential application of this assay to clinical chemosensitivity testing is limited (Carmichael et al., 1987; . In fact, it would likely not be possible to perform the assay as described by others in the majority of clinical samples, because of the low seeding cell densities commonly used. The importance of having the cells in exponential growth phase during the assay period has been emphasised. However, the majority of samples derived from patients will not be growing exponentially. Carmichael et al. (1987) reported high coefficients of variation (15% on octuplicate determinations) when the MTT assay was used for sensitivity testing of cell lines that grow in suspension, such as SCLC. However, in the present study we found that the coefficients of variation on quadruplicate determinations were usually less than 4%. There are a number of possible explanations for this discrepancy. In the Carmichael study, DMSO was used to solubilise the formazan crystals. We have found that DMSO increased absorbance values, but also increased the intraexperimental variation. Futhermore, when DMSO is used, most of the medium must be removed from the wells prior to the addition of DMSO. It would be difficult to avoid removing some cells in the process, and this could contribute to the higher standard deviations observed. Finally, since low seeding cell densities are used, there could be differential cell growth in the wells during the assay period, thus increasing the coefficients of variation.
Although the intraexperiment variation reported here is less than that of other investigators, the interexperiment variation is a significant problem which needs to be considered when interpreting chemosensitivity results, and may be a limiting factor if the assay is to be applied in the clinical setting. We believe that the interassay variability is more likely to be a function of the cell lines than an inherent problem with the MTT assay. The cell lines were tested repeatedly over a period of 3 years. While no trends towards either increasing or decreasing drug sensitivity were noted over this period of time, it is possible that the drug sensitivity may have been unstable. Other potential causes of interassay variation are differences in growth rates between the cell lines, and variations in cell cycle parameters which cannot be completely controlled. These problems are more likely to produce significant artifacts when longer assay durations are employed. This was one of the considerations in our selection of a short drug incubation time. It should also be noted that it is much easier to quantitate interexperimental variation using the MTT assay than with other assays of cytotoxicity because of the ease with which multiple repeat assays can be performed.
Contamination of tumour specimens with infiltrating nonmalignant cells is a potential problem with the MTT assay, as with most other short-term assays of cytotoxicity. However, the clinical samples that we tested had very minimal contamination with non-tumour cells. The predominant nonmalignant cells in the samples received to date have been lymphocytes. Furthermore, we have shown that peripheral blood mononuclear cells (which include lymphocytes) reduce the tetrazolium dye much less than SCLC tumour cells. Thus, the chemosensitivity results of the eight clinical samples presented here represent the drug sensitivity of tumour cells. Overgrowth of fibroblasts has not occurred with the assay described here, likely because of the short drug incubation time, and the use of selective medium. Contamination of tumour samples with non-malignant cells may prove to be a more significant problem with other tumour types. However, if large numbers of contaminating non-malignant cells are present, it should be possible to remove them using a variety of cell separation procedures.
The MTT assay described here is conceptually somewhat different than that developed by Cole (1986) for chemosensitivity testing of human lung cancer cell lines. Cole's method uses lower seeding cell densities and a longer drug incubation period. Thus, it measures a combination of drug-induced cytotoxicity and inhibition of cell growth. In the present study, a shorter drug incubation time was used, measuring primarily cytotoxicity. Tumour samples obtained directly from patients cannot necessarily be expected to proliferate in tissue culture.
The relative resistance to natural product drugs of H69AR compared to its parent cell line NCI-H69 appears to be less striking than originally reported by Mirski et al. (1987) . There are two reasons for this discrepancy. Firstly, we have expressed our data as AUC's, whereas Mirski et al. expressed their data in terms of IC50's. We have shown that the AUC relates most closely to the logarithm of the IC50 (Lam et al., 1989) . Thus, relative resistance values using the IC50 may appear much greater than when using the AUC. The second reason is that the MTT assay performed here is quite different than that used by Mirski et al., as discussed above. Using the assay as described here we found that H69AR was cross resistant to the same spectrum of drugs as found by Mirski et al., with the exception of mitoxantrone. We did not find H69AR to be cross resistant to this particular drug, whereas Mirski et al., found it to be cross resistant. The reasons for this discrepancy are unclear at the present time.
Sixteen SCLC cell lines were used for comparative chemosensitivity studies. These include lines established from patients with a spectrum of clinically drug sensitive and drug resistant disease. Only one of these lines (H69AR) had undergone in vitro selection for drug resistance. As well, although all of the cell lines are examples of SCLC, and were treated as such, they represent a pathologic spectrum, ranging from one cell line which was difficult to distinguish from an atypical carcinoid tumour, to one which was difficult to distinguish from large cell anaplastic carcinoma. From a clinical, pathological and biological point of view, SCLC is a heterogeneous disease. We believe that if one is to make clinically relevant conclusions regarding the spectrum of clinical drug responsiveness of SCLC cell lines, it is important to include a large number of cell lines representative of the complete pathologic and clinical spectrum of the disease.
The comparative chemosensitivity studies of these SCLC cell lines reveal some interesting patterns of drug sensitivity and resistance. In particular, one cell line, NCI-H209, stood out as the most sensitive to most of the drugs tested, including natural products, alkylating agents, and platinum compounds. The cell line H69AR, which had been selected in adriamycin, was the most resistant to a number of natural product drugs. Because it is feasible to test multiple drugs, this assay has the potential to reveal valuable information regarding the incidence of multidrug resistance in the clinical setting.
A number of investigators (Batist et al., 1986; Carmichael et al., 1988; Carney et al., 1983; Ruckdeschel et al., 1987; Tsai et al., 1989) have found a close correlation between chemotherapy treatment status and the relative in vitro chemosensitivity of the cell line derived from that patient. We found that cell lines established from untreated patients were more sensitive to nearly all of the drugs than lines established from treated patients. However, the results were statistically significant for only two of the drugs, and the differences for most of the drugs were not striking.
It is not possible on the basis of data presented here to make any clinical correlations on clinical samples. It would also be premature to attempt to make any definitions of in vitro sensitivity and resistance on the basis of data from such a small number of patients. Studies currently in progress of clinical chemosensitivity testing in haematologic malignancies should give a definitive answer regarding clinical correlations using this assay.
In summary, we have shown that the MTT assay can be applied to in vitro chemosensitivity testing of SCLC lines and fresh clinical samples. While some technical problems remain, this assay may have potential applications for predictive chemosensitivity testing.
